Logo image of BHVN

BIOHAVEN LTD (BHVN) Stock Fundamental Analysis

USA - New York Stock Exchange - NYSE:BHVN - VGG1110E1079 - Common Stock

10.64 USD
+1.09 (+11.41%)
Last: 12/8/2025, 3:33:04 PM
Fundamental Rating

1

Taking everything into account, BHVN scores 1 out of 10 in our fundamental rating. BHVN was compared to 531 industry peers in the Biotechnology industry. BHVN may be in some trouble as it scores bad on both profitability and health. BHVN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

BHVN had negative earnings in the past year.
BHVN had a negative operating cash flow in the past year.
BHVN had negative earnings in each of the past 5 years.
In the past 5 years BHVN always reported negative operating cash flow.
BHVN Yearly Net Income VS EBIT VS OCF VS FCFBHVN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200M -400M -600M -800M

1.2 Ratios

The Return On Assets of BHVN (-190.68%) is worse than 89.27% of its industry peers.
Industry RankSector Rank
ROA -190.68%
ROE N/A
ROIC N/A
ROA(3y)-101.1%
ROA(5y)-112.04%
ROE(3y)-133.7%
ROE(5y)-344.72%
ROIC(3y)N/A
ROIC(5y)N/A
BHVN Yearly ROA, ROE, ROICBHVN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2K 4K 6K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BHVN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BHVN Yearly Profit, Operating, Gross MarginsBHVN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, BHVN has more shares outstanding
BHVN has more shares outstanding than it did 5 years ago.
There is no outstanding debt for BHVN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
BHVN Yearly Shares OutstandingBHVN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
BHVN Yearly Total Debt VS Total AssetsBHVN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -10.63, we must say that BHVN is in the distress zone and has some risk of bankruptcy.
BHVN has a worse Altman-Z score (-10.63) than 74.95% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -10.63
ROIC/WACCN/A
WACCN/A
BHVN Yearly LT Debt VS Equity VS FCFBHVN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

2.3 Liquidity

A Current Ratio of 2.86 indicates that BHVN has no problem at all paying its short term obligations.
With a Current ratio value of 2.86, BHVN is not doing good in the industry: 67.04% of the companies in the same industry are doing better.
A Quick Ratio of 2.86 indicates that BHVN has no problem at all paying its short term obligations.
BHVN has a worse Quick ratio (2.86) than 65.16% of its industry peers.
Industry RankSector Rank
Current Ratio 2.86
Quick Ratio 2.86
BHVN Yearly Current Assets VS Current LiabilitesBHVN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.72% over the past year.
EPS 1Y (TTM)18.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.35% on average over the next years. This is quite good.
Based on estimates for the next years, BHVN will show a very strong growth in Revenue. The Revenue will grow by 148.08% on average per year.
EPS Next Y24.83%
EPS Next 2Y27.14%
EPS Next 3Y19.35%
EPS Next 5Y14.35%
Revenue Next Year-77.28%
Revenue Next 2Y129.58%
Revenue Next 3Y181.97%
Revenue Next 5Y148.08%

3.3 Evolution

BHVN Yearly Revenue VS EstimatesBHVN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
BHVN Yearly EPS VS EstimatesBHVN Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

BHVN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year BHVN is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BHVN Price Earnings VS Forward Price EarningsBHVN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BHVN Per share dataBHVN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -2 -4 -6

4.3 Compensation for Growth

BHVN's earnings are expected to grow with 19.35% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.14%
EPS Next 3Y19.35%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BHVN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIOHAVEN LTD

NYSE:BHVN (12/8/2025, 3:33:04 PM)

10.64

+1.09 (+11.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10 2025-11-10/bmo
Earnings (Next)03-02 2026-03-02/amc
Inst Owners64.33%
Inst Owner Change0%
Ins Owners9.18%
Ins Owner Change3.99%
Market Cap1.41B
Revenue(TTM)N/A
Net Income(TTM)-780.11M
Analysts81.67
Price Target19.95 (87.5%)
Short Float %10.94%
Short Ratio3.33
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.24%
Min EPS beat(2)-0.56%
Max EPS beat(2)15.03%
EPS beat(4)1
Avg EPS beat(4)-6.61%
Min EPS beat(4)-25.54%
Max EPS beat(4)15.03%
EPS beat(8)2
Avg EPS beat(8)-23.73%
EPS beat(12)3
Avg EPS beat(12)-28.73%
EPS beat(16)4
Avg EPS beat(16)-30.81%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-57.76%
PT rev (3m)-57.04%
EPS NQ rev (1m)26.91%
EPS NQ rev (3m)26.21%
EPS NY rev (1m)10.73%
EPS NY rev (3m)9.79%
Revenue NQ rev (1m)-59.4%
Revenue NQ rev (3m)-63.46%
Revenue NY rev (1m)-66.87%
Revenue NY rev (3m)-71.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-7.6
EYN/A
EPS(NY)-3.6
Fwd EYN/A
FCF(TTM)-4.9
FCFYN/A
OCF(TTM)-4.9
OCFYN/A
SpS0
BVpS-0.13
TBVpS-0.28
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -190.68%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-101.1%
ROA(5y)-112.04%
ROE(3y)-133.7%
ROE(5y)-344.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.71%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.86
Quick Ratio 2.86
Altman-Z -10.63
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)177.45%
Cap/Depr(5y)891.42%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.53%
EPS Next Y24.83%
EPS Next 2Y27.14%
EPS Next 3Y19.35%
EPS Next 5Y14.35%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-77.28%
Revenue Next 2Y129.58%
Revenue Next 3Y181.97%
Revenue Next 5Y148.08%
EBIT growth 1Y6.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.49%
EBIT Next 3Y14.98%
EBIT Next 5Y11.23%
FCF growth 1Y-120.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-122.25%
OCF growth 3YN/A
OCF growth 5YN/A

BIOHAVEN LTD / BHVN FAQ

What is the fundamental rating for BHVN stock?

ChartMill assigns a fundamental rating of 1 / 10 to BHVN.


What is the valuation status for BHVN stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOHAVEN LTD (BHVN). This can be considered as Overvalued.


What is the profitability of BHVN stock?

BIOHAVEN LTD (BHVN) has a profitability rating of 0 / 10.


What is the financial health of BIOHAVEN LTD (BHVN) stock?

The financial health rating of BIOHAVEN LTD (BHVN) is 2 / 10.


What is the earnings growth outlook for BIOHAVEN LTD?

The Earnings per Share (EPS) of BIOHAVEN LTD (BHVN) is expected to grow by 24.83% in the next year.